


LONGEVITY INDUSTRY 2.0



BOOK TEASER

DeepTech Engineering the Accelerated Trajectory of Human Longevity:
The Blueprint and Pathway from Longevity Industry 1.0 to 2.0

DMITRY
KAMINSKIY



DEEP KNOWLEDGE GROUP



2010-2023: Evolution of the Longevity Industry From Zero to 1.0

- The Industrialization of Longevity
- The Current State of Longevity Science, Business, Finance, and Practical Applications
- Longevity Becomes a National Priority Item for the Strategic Agenda of Progressive Governments
- Transforming the Challenge and Deficit of Aging into the Opportunity and Asset of Longevity
- Defining and De-Risking: Hype vs. Reality

2023-2027: DeepTech Engineering the Accelerated Trajectory of Human Longevity – The Blueprint and Pathway From 1.0 to 2.0

- Evolution From 1.0 (Defining the Industry) to 2.0 (Applying the Framework for Longevity Industrialization, Investment De-Risking, and National Longevity Economy Development)
- The Evolution From Longevity Start-Ups to Multi-Trillion Dollar Longevity Corporations
- Future of Longevity Finance: Financial Instruments to Bridge the Longevity Liquidity Gap
- The Rise of Longevity Technocracies and the Concept of "Longevity Valley"
- Engineering Market-Ready Pathways for Practical Human Longevity by 2030

About the Book: Introducing Longevity Industry 2.0

PART I.

The Evolution From 1.0 (Defining the Industry) to 2.0 (Applying the Framework for Industry Harmonization and Investment De-Risking)

- *How to Apply the Longevity Industry Frameworks Presented in Longevity Industry 1.0 To Optimize Strategic Decision-Making and Direct the Industry's Evolving Future*
- *Major Challenges, Opportunities, and Recommendations for Longevity Companies, Investors, Progressive Governments, and Policymakers*
- *Longevity as a Major Component and Outcome of the 5th Industrial Revolution*
- *Using Tangible Longevity Industry Analytics To De-Risk Investments, Execute Relevant Industrial Strategies and National Development Plans, and Achieve Tangible Results in Practical Healthy Human Longevity by the Year 2030*

PART III.

The Longevity Financial Industry: Past, Present, and Future Longevity Stock Exchange, Index, and Financial Instruments

- *Modern Tools To Bridge the Longevity Industry's Big Liquidity Gap*
- *Benchmarking of Outdated, Modern, and Progressive Approaches*
- *Financial Futurism – Engineered Solutions to the Big Liquidity Gap*
- *Longevity Stock Exchange, Investment Bank, Index Fund, and Financial Instruments*
- *Longevity Futures, Shorting, ETFs, Micro-Index Funds, and Technology Marketplaces*
- *The Future of Longevity Financial Instruments: Derivatives Tied to the Longevity Industry, Sectors, Technologies, and Entire National Healthcare Systems, Pension Systems, Population-Level National Healthy Longevity, and Longevity Economies*

PART II.

Longevity Policy and Governance: Rise of Longevity Technocracies and the Concept of the “Longevity Valley”

- *The Rise of Progressive Longevity MegaHubs and Technocracies*
- *The Concept of the Longevity Valley: The World's First Full-Scale Longevity MegaHub*
- *Benchmarking National and Local Industrial Strategies, Policies, and Initiatives*
- *Updated International Benchmarking and National Healthy Longevity Forecasts*
- *How Longevity Will Determine the Outcome of National Elections by the Year 2025*
- *Longevity Ethics: How Potential Negative Societal Outcomes Resulting from Longevity Can be Proactively Optimized to Ensure Global Longevity Harmonization*
- *Longevity Policy Big Data Analytics Dashboards (SWOT, Monitoring & Optimization)*

PART IV.

Longevity Medicine and Technology: Engineering Market-Ready Pathways for Practical Human Longevity by 2030

- *Existing, Available, and Off-the-Shelf Technologies, Techniques, and Approaches for Optimizing Your Personal Healthy Longevity Today*
- *Biomarkers of Human Longevity: Market-Ready Solutions for Companies, Investors, and National and Municipal Governments To Validate and Track Applications, Technologies, and Approaches to Practical Healthy Human Longevity*
- *The Longevity Industry's Biggest Systemic Risk: Reliance on Animal Validation*
- *Integral Platforms and Modern Technologies for Safe Human Experimentation and Reliable Validation of Longevity Technologies for Tangible Investment Decision-Making, Investment and IPO De-Risking*

About the Book: Introducing Longevity Industry 2.0

PART V. The Science of Longevity: 2023-2025

- *Longevity Science (R&D Landscape Overview) 2023*
- *The Current State of Longevity Clinical Trials*
- *The Problem and Promise of Longevity Science: The Risk of Overreliance on Model Organisms and the Needed Paradigm Shift from Mice to Men*
- *AI as the Major Accelerative Factor for Longevity Science R&D*
- *The Future of Geroscience and Longevity R&D: Mice vs. Men and the Paradigm Shift in Scientific Community Mindset Toward Practical Human Validation*

PART VII. Technologizing Human Performance: Pathway From Human 1.0 to Human 2.0

- *Convergences Between Longevity and Performance Enhancement*
- *NeuroTech Special Case Study: Optimizing Cognitive Performance*
- *SpaceTech Special Case Study: The Pathway From Mice on Earth to Men on Mars*
- *AgeTech for All: Market Ready Approaches for Optimizing Non-Biomedical Aspects of Human Capacity and Performance*
- *The Inevitable Intersection Between Human Health and Performance*
- *Defining and Executing the Practical Pathway from Humanity 1.0 to Humanity 2.0*

PART VI. Longevity Medicine and Technology: Engineering Market-Ready Pathways for Practical Human Longevity by 2030

- *The Past, Present, and Future of Practical Healthy Human Longevity*
- *Biomarkers of Human Longevity: Market-Ready Solutions for Companies, Investors, and National and Municipal Governments*
- *The Need for a Fundamental Paradigm Shift in the Mindsets of Longevity Scientists and Practitioners*
- *Mice vs. Men: Integral Platforms for Safe Human Experimentation and Validation for Tangible Investment Decision-Making and De-Risking*


PART VIII. Ethics and Society: Optimizing the Impact of Longevity on Global Humanity

- *The Ethical and Societal Pros and Cons of Longevity*
- *Best- and Worst-Case Outcomes of the Industrialization of Healthy Human Longevity*
- *Neutralizing the Potential Negative Outcomes of Longevity*
- *The Framework for Optimizing the Positive Outcomes and Neutralizing the Negative Consequences of Global Longevity Industrialization*
- *Social Psychology as the Major Roadblock or Accelerating Factor Impacting the Societal and Ethical Outcomes of Longevity Industry*
- *Embracing the Engineering and DeepTech Mindset of Societal Development*

About the Book: Introducing Longevity Industry 2.0

In *Longevity Industry 1.0: Defining the Biggest and Most Complex Industry in Human History*, we distilled the complex assembly of deep market intelligence and industry knowledge that Deep Knowledge Group has developed over the past 8 years into a full-scope understanding of the Global Longevity Industry. We showed the public exactly how the international consortium of commercial and non-profit entities managed to define the overwhelmingly complex and multidimensional Longevity Industry for the first time, and how they created a tangible framework for its systematization and forecasting.

This sequel charts Deep Knowledge Group's ongoing work toward formulating the pathway to Longevity Industry 2.0; outlines several issues (and proposed solutions) that we believe constitute the foremost bottlenecks and risks to a continuing positive trajectory of development in Longevity science, policy, industry, finance and investment; and presents a preliminary view of the frameworks we are developing to help strategic decision-makers, industry participants, and the general public take greater control over the actual, real-world development of both the Longevity Industry and Healthy Human Longevity.



Longevity Industry 2.0 – Foreword by Dmitry Kaminskiy

In my 2020 book [*Longevity Industry 1.0: Defining the Biggest and Most Complex Industry in Human History*](#), we distilled the complex assembly of deep market intelligence and industry knowledge that [*Deep Knowledge Group*](#) and its Longevity-focused subsidiaries (including [*Longevity.Capital*](#) and [*Aging Analytics Agency*](#)) have developed over the past 8 years into a full-scope understanding of the Global Longevity Industry.

Our work toward defining the Longevity Industry, and our work in creating and publicly disclosing our internally-developed framework for tangible analysis, systematization, and forecasting of the industry in order to optimize our own strategic decision making in this domain, remains as important today as it was when we published the book. Despite the fact that the Longevity Industry has witnessed unprecedented levels of growth and maturation over the past decade, the term Longevity itself, and its fundamental definition, still remains unclear to many people (and to investors in particular), who associate Longevity with such topics as typical anti-aging skin creams and the fitness and wellness industries.

In reality, Longevity is the deepest of all DeepTech sectors, and occupies the very forefront of advanced biomedicine, sitting at the intersection of many domains of DeepTech and Frontier Technologies. The industry's intersection with, and reliance upon, advanced technologies does not, however, exclude or preclude the fact that it is also deeply interconnected with specific behavioural and lifestyle interventions. What it does mean, however, is that the scope and sophistication of technology-based tools and methods of optimizing day-to-day Healthy Longevity are large, rapidly increasing, and much broader (and deeper) than many people may realize, extending far beyond simplistic approaches involving diet, exercise and supplements, encompassing DeepTech products and services that are becoming increasingly available to the consumer.

Whereas Longevity Industry 1.0 charted the inception and rise of the industry up to 2020, and provided the methodology and framework for defining and analyzing the industry, its sequel, [*'Longevity Industry 2.0: DeepTech Engineering the Accelerated Trajectory of Human Longevity - The Blueprint and Pathway from Longevity Industry 1.0 to 2.0'*](#), outlines Deep Knowledge Group's recent work towards formulating the pathway to Longevity Industry 2.0, and presents the framework for safeguarding the sector's current upward trajectory and ensuring its optimized, sustainable growth towards its next stage and the realization of its practical benefits for humanity by the year 2030. The book outlines several issues (and proposed solutions) that we believe constitute the foremost bottlenecks and risks to a continuing, positive trajectory of development in Longevity science, policy, industry, finance and investment, and present a preliminary preview of the frameworks we are developing to help strategic decision makers, industry participants and the general public take greater control over the actual, real-world development of both the Longevity Industry and Healthy Human Longevity.

Meanwhile, the next book in the series, *'Longevity Industry 3.0: Stable Acceleration of Longevity Industrialization to Achieve its Practical Humanitarian Impact by the Year 2027'*, will present the framework and toolsets required to maximize the positive societal benefits and neutralize the potentially detrimental consequences of Longevity, and how to accelerate its major practical impacts (including economic growth and stabilization and additional socially-inclusive HALE and QALY-years for humanity ahead of standard timelines - not in 10 years, but in 6.

Table of Contents

Foreword	1	9. Benchmarking Progressiveness of National, Regional and Municipal Longevity Industrial Strategies and National Development Plans	135
Key Concepts	5	10. The Rise of Longevity Valley: Analysis of Most Ideal Regions to Become the First Fully Integrated Longevity Industry Hub	145
PART I - The Evolution from 1.0 (Defining the Industry) to 2.0 (Applying the Framework for Industry Harmonization and Investment De-Risking)	15	11. Longevity Governance Big Data Analytics Dashboard - Monitoring, SWOT Analysis and Practical Recommendation System	155
1. DeepTech Engineering the Practical Pathway From 1.0 to 2.0	25	12. Ethics, Policy and Societal Pros and Cons: How Potential Negative Outcomes of Optimized Global Longevity Can be Neutralized	165
2. Applying Deep Knowledge Group's Longevity Industry Framework	35	PART IV - Longevity Financial Industry: Past, Present and Future	175
3. Longevity Industry and the Path to the Fifth Industrial Revolution	45	13. Longevity Financial Industry Big Data Analytics Dashboard	190
4. Analytics to Engineer the DeepTech Trajectory of Longevity 2.0: The Evolution of Deep Knowledge Group's Longevity Analytics	55	14. Benchmarking: Traditional, Modern and Progressive Approaches	200
5. Achieving Tangible Results in Practical Human Longevity by 2030	65	15. Financial Futurism - Engineered Solutions to the Big Liquidity Gap: Stock Exchange, Investment Bank, Index Fund & Financial Instruments	210
PART II - The Business of Longevity 2023-2025	75	PART V - The Science of Longevity: 2023 - 2025	220
6. Global Longevity Industry Overview 2023	90	16. Longevity Science (R&D Landscape Overview) 2023	230
7. Longevity Market Maturation: Top Longevity Deals, Investments, IPOs and Industry Events 2022-2023	100	17. The Current State of Longevity Clinical Trials	240
PART III - Longevity Policy & Governance: Rise of Longevity Technocracy	110	18. The Future of Geroscience and Longevity R&D: Mice vs. Men, and the Paradigm Shift in Scientific Community Mindset toward Practical	250
8. Longevity Will Define & Decide the Fate of Nations in Next 10 Years	125		

Table of Contents

PART VI - Longevity Medicine and Technology: <i>Engineering Market-Ready Pathways for Practical Human Longevity by the Year 2030</i>	260	29. Neutralizing Potential Negative Outcomes of Longevity	415
19. The Past, Present & Future of Practical Healthy Human Longevity	270	- Overpopulation (The Earth Needs <i>More</i> People, Not Less)	430
20. Biomarkers of Human Longevity: Market-Ready Solutions for Companies, Investors, and National and Municipal Governments	280	- Famine (Technological Solutions to Unlimited Agriculture)	440
21. Mice vs. Men: Integral Platforms for Safe Human Experimentation and Validation for Tangible Investment Decision Making & De-Risking	295	- Pollution (Technological Solutions to Global Toxification)	450
PART VII - Technologizing Human Performance: <i>Pathway from Human 1.0 to Human 2.0</i>	305	- Equality: The Rich vs Poor Divide	460
22. Convergences Between Longevity and Performance Enhancement	315	30. The Framework for Optimizing Positive Outcomes & Neutralizing Negative Consequences of Global Longevity Industrialization	470
23. NeuroTech Special Case Study: Optimizing Cognitive Performance	325	31. Social Psychology as the Major Roadblock <i>or</i> Accelerating Factor Impacting the Societal and Ethical Outcomes of Longevity Industry	480
24. SpaceTech Special Case Study: The Pathway from Mice on Earth to Men on Mars	335	- Conservatism and Fear of Innovation as the Root Cause of Societal Risk, Stagnation and Decline	490
25. AgeTech for All: Market Ready Approaches for Optimizing Non-Biomedical Aspects of Human Capacity and Performance	345	- Embracing the Engineering and DeepTech Mindset of Human Technological and Industrial Development	500
26. The Inevitable Intersection Between Human Health and Performance	360	APPENDIX - Getting More From Longevity Industry 2.0, and the Pathway to Longevity Industry 3.0	510
PART VII - Ethics & Society: <i>Optimizing the Impact of Longevity on Global Humanity</i>	375	APPENDIX: Overview of Deep Knowledge Group Longevity Activities During 2022/2023	525
27. The Ethical and Societal Pros and Cons of Longevity	390	APPENDIX - Longevity Dashboards	535
28. Best and Worst Case Outcomes Resulting from the Full Scale Industrialization of Healthy Human Longevity	400	About Deep Knowledge Group	550
		About the Author	560

About the Author (Dmitry Kaminskiy)

Dmitry Kaminskiy is an innovative entrepreneur, investor, author and philanthropist dedicated to impact investment and ethical business, with a focus on engineering the accelerated trajectory of progressive technological development for the benefit of humanity.

Mr. Kaminskiy is a co-founder and managing partner of **Deep Knowledge Group** - a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, Precision Medicine, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, policy and philanthropy.

He leads the activities of the consortium's venture arms - **Deep Knowledge Ventures**, an investment fund focused on DeepTech and advanced science projects, and **Longevity.Capital**, which prioritizes the convergence of Longevity and Artificial Intelligence, areas in which it has unparalleled investment and exit strategies.

He is a frequent speaker on the topics of AI and Longevity, including conferences organized in London by The Economist "Aging Societies and The Business of Longevity", Financial Times "Smart Machines vs Smart People", at the Future Finance Forum in Seoul "AI in Finance", "Precision Medicine World Conference" in Silicon Valley, as well as several others at Oxford and Cambridge Universities.

Mr. Kaminskiy serves as managing trustee of **Biogerontology Research Foundation**, the UK's oldest Longevity focused charity, and Head of International Development of the Longevity International UK - the Secretariat for the UK All-Party Parliamentary Group for Longevity, the world's first official parliamentary group specifically dedicated to Longevity.



PART I: The Evolution from 1.0 (*Defining the Industry*) to 2.0 (*Applying the Framework for Industry Harmonization and Investment De-Risking*)

- How to Apply the Longevity Industry Frameworks Presented in Longevity Industry 1.0 to Optimize Strategic Decision Making and Direct the Industry's Evolving Future
- Major Challenges, Opportunities and Recommendations for Longevity Companies, Investors, Progressive Governments and Policy-Makers
- Longevity as a Major Component and Outcome of the Fifth Industrial Revolution
- Using Tangible Longevity Industry Analytics to De-Risk Investments, Execute Relevant Industrial Strategies and National Development Plans
- Market-Ready Tools, Technologies, Analytical Dashboards and Frameworks to Achieve Tangible Results in Practical Healthy Human Longevity by the Year 2030

The image displays a 3D visualization of a 10x10x10 cube, representing a 1000-dimensional space. The top face is labeled with coordinates Z11 through Z34. The front face is labeled with coordinates X11 through X12. The right face is labeled with coordinates Y11 through Y12. The cube is divided into smaller sections, each containing text labels for various scientific and technological domains. The labels are organized into a grid-like structure, with some sections spanning multiple dimensions. The overall structure is a 10x10x10 cube, with the top face labeled Z11 through Z34, the front face labeled X11 through X12, and the right face labeled Y11 through Y12.

Longevity Landscape Framework

Geroscience R&D

Rejuvenation
Biotechnology

Basic Research on
Biology of Ageing

Geroprotectors

Regenerative
Medicine

Nutraceuticals

Gene Therapy

P4 Medicine

Personalized
Diagnostics

Personalized HALE
and QALE Estimation

Personalized
Prognostics

Personalized in vivo
and in silico Drug
Testing

Preventive Therapies

Participatory Medicine

AgeTech

NeuroTech

Cognitive
Enhancement

Smart Homes

NextGen Mobile Apps
for the Elderly

Continuing Education

Entertainment for the
Elderly

Longevity WealthTech

Financial Planning

Asset Management

Micro-Investments

Digital Brokers

AI-Driven Assistants

Long-Term Securities

Longevity Finance

Longevity Index Fund

Longevity Hedge Fund

Longevity Stock
Exchange

AgeTech Bank

Longevity Derivatives

Longevity Investment
Bank

Longevity Governance

Pension Plans

National Healthcare
Budgets

Longevity
Development
Strategies

Elderly Care Programs

National Insurance

Elderly Education

PART II: The Present and Future of Longevity Policy & Governance: The Rise of Longevity Technocracies, the Concept of 'Longevity Valley'


- The Rise of Progressive Longevity MegaHubs and Technocracies
- The Concept of Longevity Valley: The World's First Full-Scale Longevity MegaHub
- Benchmarking National and Local Industrial Strategies, Policies and Initiatives
- Updated International Benchmarking and Forecasts of National Healthy Longevity
- How Longevity Will Determine the Outcome of National Elections by the Year 2025
- Longevity Ethics: How Potential Negative Societal Outcomes Resulting from Longevity Can be Proactively Optimized to Ensure Socially Inclusive and Ethical Global Longevity Harmonization
- Longevity Policy Big Data Analytics Dashboards (SWOT Analysis, Continuous Monitoring, Regional Comparisons and Practical Recommendation Packs)



PART III: The Longevity Financial Industry's Past, Present and Future


Longevity Stock Exchange, Index and Financial Instruments

- Modern Tools to Bridge the Longevity Industry's Big Liquidity GAP
- Benchmarking of Outdated, Modern and Progressive Approaches
- Updated recommendations and forecasts for Investment and Retail Banks, Insurance Companies, Pension Funds, Financial Services and FinTech Companies
- Financial Futurism - Engineered Solutions to the Big Liquidity Gap
- Longevity Stock Exchange, Investment Bank, Index Fund & Financial Instruments
- Longevity Futures, Shorting, ETFs, Micro-Index Funds, & Technology Marketplaces
- The Future of Longevity Financial Instruments: Derivatives Tied to the Longevity Industry, Sectors, Technologies, and entire National Healthcare Systems, Pension Systems, Population-level National Healthy Longevity & Longevity Economies




PART IV: The Science of Longevity: 2023 - 2025

- Longevity Science (R&D Landscape Overview) 2023
- The Current State of Longevity Clinical Trials
- The Problem and Promise of Longevity Science
- The Risk of Overreliance on Model Organisms and the Needed Paradigm Shift from Mice to Men
- AI as the Major Accelerative Factor for Longevity Science R&D
- The Future of Geroscience and Longevity R&D
- Mice vs. Men, and the Paradigm Shift in Scientific Community Mindset toward Practical Human Validation
- New Platforms and Approaches for Scientific Peer-Reviewed Practitioner Self-Experimentation and Therapeutic & Diagnostic Validation



PART V: Longevity Medicine and Technology: Engineering Market-Ready Pathways for Practical Human Longevity by 2030

- Existing, Available and Off-the-Shelf Technologies, Techniques and Approaches for Optimizing Your Personal Healthy Longevity Today
- Biomarkers of Human Longevity: Market-Ready Solutions for Companies, Investors, and National and Municipal Governments to Validate And Track Applications, Technologies and Approaches to Practical Healthy Human Longevity
- The Longevity Industry's Biggest Systemic Risk: Reliance on Animal Validation
- Integral Platforms and Modern Technologies for Safe Human Experimentation and Reliable Validation of Longevity Technologies for Tangible Investment Decision Making, Investment and IPO De-Risking, and Industry Stabilization and Safeguarding



Biomarkers of Human Longevity: Tangible Approaches to Therapy Validation, Tracking Population-Health & Investment De-Risking

In 2019, Deep Knowledge Group's Longevity-focused analytical subsidiary, Aging Analytics Agency, produced and released '[Biomarkers of Longevity: Current state, Challenges and Opportunities Landscape Overview 2019](#)', which market the first public disclosure of its ongoing study into the current state and future trajectory of this domain. That special case study that performed a benchmarking of human biomarkers of aging and Longevity according to their degree of actionability (a weighted metric that analyzed their level of precision and accuracy vs. factors that determine how easily they can be implemented on a massive scale, such as cost, invasiveness, and broad adoptability).

In Q1 2021, Aging Analytics Agency followed up on this report with a new, open-access, extended and enhanced edition, titled '[The Rising Wave of Human Biomarkers of Longevity: Landscape Overview 2021](#)', along with an associated IT-Platform to make the report's key conclusions, take-aways and predictions maximally usable and understandable for Longevity scientists, companies, investors, policy makers and the general public.

The Rising Wave of Human Biomarkers of Longevity: Landscape Overview 2021


Analytical Report

Increasing Potential of Longevity Biomarkers in Practical Applications



www.longevity.international
www.aginganalytics.com
www.dkvglobal


Landscape of Companies Developing Longevity Biomarkers



PART VI: Longevity Medicine and Technology


Market-Ready Solutions for Practical Human Longevity

- Current State and Future of Practical Human Longevity
- Longevity Biomarkers: Market-Ready Tools for Optimizing Personal and National Healthy Longevity
- Integral Platforms for Safe Human Experimentation and Validation
- The use of Safe Human Validation Platforms for Tangible Investment Decision Making, Separating Hype vs. Reality, and Safeguarding/Stabilizing Longevity IPOs
- NeuroTech and Longevity NeuroTech
- Performance Enhancement and Cognitive Optimization
- SpaceTech and Space Medicine
- Space Medicine as Modern Precedent for Safe Human Experimentation
- Technical Convergence in Space Medicine (Protection & Prevention of Astronauts) and Practical Longevity
- Advanced Cosmetics and FemTech



PART VII: Technologizing Human Performance: The Pathway to Human 1.0 Human 2.0

- *Convergences Between Longevity and Performance Enhancement*
- *NeuroTech Special Case Study: Optimizing Cognitive Performance*
- *SpaceTech Special Case Study: The Pathway from Mice on Earth to Men on Mars*
- *AgeTech for All: Market Ready Approaches for Optimizing Non-Biomedical Aspects of Human Capacity and Performance*
- *Increasing Market Readiness of Longevity Technologies Will Pave the Way for Their Re-application Toward Human Performance*
- *The Inevitable Intersection Between Human Health and Performance*
- *Defining and Executing the Practical Pathway from Humanity 1.0 to Humanity 2.0*




PART VIII: Ethics and Society - Optimizing the Impact of Longevity on Global Humanity

- *The Ethical and Societal Pros and Cons of Longevity*
- *Best and Worst Case Outcomes of the Industrialization*
- *Neutralizing Potential Negative Outcomes of Longevity” Overpopulation (The Earth Needs More People, Not Less), Pollution (Technological Solutions to Global Toxification), and Equality: The Rich vs Poor Divide*
- *The Framework for Optimizing Positive Outcomes & Neutralizing Negative Consequences of Global Longevity Industrialization*
- *Social Psychology as the Major Roadblock or Accelerating Factor Impacting the Societal and Ethical Outcomes of Longevity Industry*
- *Conservatism (Fear of Innovation) as Root Cause of Stagnation and Decline*
- *Embracing the Engineering and DeepTech Mindset of Human Technological and Industrial Development*



APPENDIX: Longevity Dashboards

- *Public Longevity Companies Investment Big Data Analytics Dashboard*
- *UK Longevity Governance Big Data Analytics Dashboard*
- *Longevity Finance Big Data Analytics Dashboard*
- *Longevity Investment Big Data Analytics Dashboard*
- *Global Longevity Governance Dashboard*





UK Longevity Governance Big Data Analytics Dashboard



Public Longevity Companies Investment Big Data Analytics Dashboard

The Public Longevity Companies Investment Big Data Analytics Dashboard represents a significant advancement in science and technology by addressing the growing need for comprehensive and actionable market intelligence in the longevity and aging industry. Traditional approaches to investment analysis in this field are often limited by manual research methods and lack real-time insights. This project seeks to overcome these limitations by leveraging big data analytics and cutting-edge technologies to gather, process, analyze, and visualize information from various sources. To ensure the accuracy and reliability of the data, the project team implemented a robust data cleansing process, taking into account factors such as data quality, completeness, and consistency. By employing state-of-the-art natural language processing techniques, the dashboard is capable of extracting and analyzing relevant information from an extensive range of textual sources, including news articles, scientific publications, financial reports, and social media platforms.



2023-2027: DeepTech Engineering The Accelerated Trajectory of Human Longevity - The Blueprint and Pathway from 1.0 to 2.0

- Evolution from 1.0 (Defining the Industry) to 2.0 (Applying the Framework for Longevity Industrialization, Investment De-Risking and National Longevity Economy Development)
- The Evolution from Longevity Start-ups to Multi-Trillion Dollar Longevity Corporations
- Future of Longevity Finance: Financial Instruments to Bridge the Longevity Liquidity Gap
- The Rise of Longevity Technocracies and the Concept of 'Longevity Valley'
- Engineering Market-Ready Pathways for Practical Human Longevity by 2030

2025-2030: Stable Acceleration of Longevity Industrialization to Achieve its Practical Humanitarian Impact by the Year 2027

- Evolution from 2.0 (Stabilizing the Industry) to 2.0 (Optimizing the Industry and Accelerating the Realization of its Practical Impacts Ahead of Standard Timelines)
- How Longevity will Drive a Global Paradigm Shift From Capital-based Economies to Health-Adjusted Life Expectancy (HALE) & Quality-Adjusted Life Year (QALY) Economies
- Tangible Frameworks to Enable Governments to Use Longevity Industrialization as the Launch Pad Booster and Fission Reaction to Enter the 5th Industrial Revolution

www.longevity-book.com

email: contact@longevity-book.com